title: [Chemoimmunotherapy with dacarbazine and aranose combined with interferon-alpha in disseminated cutaneous melanoma].
abstract: Aranoza and dacarbazine (DTIC) monotherapy and in combinations with aranoza and interferon-alpha (IPHN-alpha) as well as DTIC and IPHN-alpha was given to 175 patients (89 males and 86 females, aged 23-78) with disseminated skin melanoma. The effectiveness of aranoza and DTIC monotherapy was practically identical. Total response to DTIC used in combination with IPHN-alpha increased insignificantly: 25.6%--in combination vs. 19.5% DTIC alone (p > 0.05). IPHN-alpha was most effective when used with aranoza (total objective response--31.7% vs. aranoza alone--16%). The best results were reported in cases heretofore untreated with cytostatic drugs. Total response (complete or partial remission) was recorded in 63% vs. 4.5% (p < 0.05) of patients who had received chemotherapy. In cases of aranoza+ IPHN-alpha treatment, complete and partial remission was reported in metastasis of the skin, subcutaneous fat, peripheral, retroperitoneal and abdominal (mesenteric) lymph nodes and lungs. There was no relapse of metastasis of the liver, intestinal tract, bones, breast or ovary.
authors.affiliation: N.N. Petrov Research Institute of Oncology, Ministry of Health of the RF, St. Petersburg.
authors.forename: M L
authors.initials: ML
authors.lastname: Gershanovich
authors.forename: M A
authors.initials: MA
authors.lastname: Akimov
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000276:immunology* / Q000627:therapeutic use*; D003606:Dacarbazine / Q000008:administration & dosage; D005260:Female; D006027:Glycosides / Q000008:administration & dosage; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage; D016898:Interferon-alpha / Q000008:administration & dosage; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D008770:Methylnitrosourea / Q000008:administration & dosage / Q000031:analogs & derivatives*; D008875:Middle Aged; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D006027:Glycosides; D007155:Immunologic Factors; D016898:Interferon-alpha; C447099:aranoza; D008770:Methylnitrosourea; D003606:Dacarbazine